期刊文献+

慢性阻塞性肺疾病与血浆纤维蛋白(原)的研究现状 被引量:4

The research situation in chronic obstructive pulmonary disease and plasma fibrinogen or fibrin
原文传递
导出
摘要 COPD是一种具有不完全可逆性气流阻塞特征的慢性炎性疾病,常伴有心血管疾病增加、静脉血栓栓塞风险和系统性炎症反应等并发症,是全球发病和死亡的主要原因之一。FEV1是在疾病严重程度和进展方面使用最广泛的的指标,鉴于其与症状和疾病进展其他方面存在较弱的相关性,探索能充分体现COPD特征的标志物更是备受关注。纤维蛋白原是急性时相反应蛋白,也是凝血系统中重要的凝血因子,纤维蛋白原与其降解产物Aα-Val^360以及纤维蛋白降解产物D-二聚体可以作为监测疾病进展和急性发作的潜力标志物。在此主要从静脉血栓栓塞以及炎症反应等方面对相关生物学标志物进行阐述,以进一步理解其在疾病发生、发展中的作用,为疾病的监测和治疗预防提供新的思路。 Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease that is characterised by airflow obstruction that is not fully reversible, often associated with an increase in cardiovascular disease, risk of venous thromboembolism and systemic inflammatory response complication, which is a major global cause of morbidity and mortality. Forced expiratory volume in one second (FEV1) is the most widely used parameter in the severity and progression of disease. The markers reflecting sufficiently the characteristics of COPD are attracted more attention considering that FEV1 correlates poorly with both symptoms and other measures of disease progression. Fibrinogen is acute phase reaction protein and important clotting factor in blood coagulation system, fibrinogen with its degradation product Aα-Val^360 and fibrin degradation product D-dimer may used as the potential markers to monitor the disease progression and exacerbation. Here we will mainly explain related biological markers in terms of venous thromboembolism and inflammatory response, further understanding of its role in disease development to provide a new thought for the monitoring and treatment of disease prognosis.
出处 《国际呼吸杂志》 2016年第2期138-141,共4页 International Journal of Respiration
基金 国家自然科学基金面上项目(81170035) 湖北省自然科学基金项目(2010CDB08903)
关键词 慢性阻塞性肺疾病 纤维蛋白原 纤维蛋白原降解产物 Chronic obstructive pulmonary disease Fibrinogen Fibrinogen degradation product
  • 相关文献

参考文献20

  • 1Duvoix A, Dickens J, Haq I, et al. Blood fihrinogen as a biomarker of chronic obstructive pulmonary disease [J]. Thorax, 2013,68(7) : 670-676. DOI: 10.1136/thoraxjnl-2012- 201871. 被引量:1
  • 2Medved L, Weisel JW, Fibrinogen and Factor XIII Subcommittee of Scientific Standardization Committee of International Society on Thrombosis and Haemostasis. Recommendations for nomenclature on fibrinogen and fibrin [J] .J Thromb Haemost, 2009, 7(2) :355-359.DOI: 10. 1111/ j. 1538-7836. 2008. 03242. x. 被引量:1
  • 3Valvi D, Mannino DM, Mullerova H, et al. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts[J]. Int J Chron Obstruct Pulmon Dis, 2012,7 : 173-182. DOI i10.2i47/COPD. S29892. 被引量:1
  • 4Engstrom G, Segelstorm N, Ekberg-Aronsson M, et al. Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study [J]. Thorax, 2009, 64 (3): 211-215, DOI: 10. 1136/thx. 2008. 102079. 被引量:1
  • 5Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD[J]. Chronic Ohstr Pulm Dis (Miami), 2015,2 ( 1 ) : 23-34. DOI : 10. 15326/jeopdf. 2.1. 2014.0138. 被引量:1
  • 6Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD[J]. N Engl J Med, 2011, 365 (13): 1184-1192. DOI: 10. 1056/ NEJMoa1105482. 被引量:1
  • 7Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination[J]. Am J Med, 2003, 114(9) : 758-762. DOI: 10. 1016/S0002-9343 (03) 00185-2. 被引量:1
  • 8Mannino DM, Valvi D, Mullerova H, et al. Fibrinogen, COPD and mortality in a nationally representative U. S. cohort [J]. COPD, 2012, 9 (4) z 359-366. DOI: 10. 3109/15412555. 2012, 668249. 被引量:1
  • 9Coughlin SR. Thrombin signalling and protease-activated reeeptors[J]. Nature, 2000, 407 (6801): 258-264. DOI: 10. 1038/35025229. 被引量:1
  • 10Fibrinogen Studies Collaboration, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis[J]. JAMA, 2005, 294 (14) : 1799-1809. DOI: 10. 1001/jama. 294.14. 1799. 被引量:1

二级参考文献47

  • 1Eng CW,Wansaicheong G,Goh SK,et al.Exclusion of acute pulmonary embolism:computed tomography pulmonary angiogram or D-dimer? Singapore Med J,2009,50:403-406. 被引量:1
  • 2Ay C,Pabinger I.Tests predictive of thrombosis in cancer.Thromb Res,2010,125:S12-15. 被引量:1
  • 3Sofia S,Baldini E,Zhuzhuni H,et al.D-dimer's role in aortic dissection.Clin Ter,2010,161:45-48. 被引量:1
  • 4Di Nisio M,Squizzato A,Rutjes AW,et al.Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism:a systematic review.J Thromb Haemost,2007,5:296-304. 被引量:1
  • 5Taira T,Taira BR,Carmen M,et al.Risk of venous thromboembolism in patients with borderline quantitative D-dimer levels.Am J Emerg Med,2010,28:450-453. 被引量:1
  • 6Prisco D,Grifoni E.The role of D-dimer testing in patients with suspected venous thromboembolism.Semin Thromb Hemost,2009,35:50-59. 被引量:1
  • 7Wells PS.Pulmonary embolism:a clinician's perspective.Semin Nucl Med,2008,38:404-411. 被引量:1
  • 8Corwin MT,Donohoo JH,Partridge R,et al.Do emergency physicians use serum D-dimer effectively to determine the need for CT when evaluating pagents for pulmonary embolism? Review of 5344 consecutive patients.AJR Am J Roentgenol,2009,192:1319-1323. 被引量:1
  • 9Perrier A.From dyspnea to pulmonary embolism.Ther Umsch,2009,66:643-647. 被引量:1
  • 10Bruinstroop E,van de Ree MA,Huisman MV.The use of D-dimer in specific clinical conditions:a narrative review.Eur J Intern Med,2009,20:441-446. 被引量:1

共引文献67

同被引文献42

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部